Glucosamine dose/concentration-effect correlation in the rat with adjuvant arthritis
© 2013 Wiley Periodicals, Inc. and the American Pharmacists Association..
There is a debate on the dose dependency, concentration-effect, hence, the beneficial effect of glucosamine (GlcN), a widely used anti-inflammatory natural product. We investigated dose/concentration-effect relationship and determined its minimum effective dose/concentration in rats with adjuvant arthritis (AA, Mycobacterium butyricum in squalene) both as preventive and ameliorating interventions. To control already emerged arthritis, rats received oral doses of placebo or 160 mg/kg.day(-1) GlcN for 6 days. For prevention, rats were orally administered 0, 20, 40, 80, or 160 mg/kg.day(-1) GlcN commencing on the day of adjuvant injection. The arthritis index (AI), serum nitrite, and body weight were recorded. Subsequently, animals were cannulated in the right jugular veins and blood samples were collected for the determination of GlcN. GlcN ameliorated and, dose-dependently, prevented AA. It also controlled nitrite. AI was inversely correlated with GlcN dose, maximum plasma concentration, and the area under the concentration curve. Minimum effective dose was approximately 40 mg/kg.day(-1) that correspond to maximum plasma concentration of 1.37 ± 0.24 mg/L, close to 1.6 mg/L reported for pharmaceutical grades of GlcN to humans. GlcN efficacy is dose and concentration dependent. If the data extrapolated to humans, a higher than the commonly tested 1500 mg/kg dosage regimen may provide more clear treatment outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:103 |
|---|---|
| Enthalten in: |
Journal of pharmaceutical sciences - 103(2014), 2 vom: 01. Feb., Seite 760-7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aghazadeh-Habashi, Ali [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 05.11.2014 Date Revised 04.03.2014 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jps.23819 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM234013281 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM234013281 | ||
| 003 | DE-627 | ||
| 005 | 20231224100346.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jps.23819 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0780.xml |
| 035 | |a (DE-627)NLM234013281 | ||
| 035 | |a (NLM)24375187 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aghazadeh-Habashi, Ali |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Glucosamine dose/concentration-effect correlation in the rat with adjuvant arthritis |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.11.2014 | ||
| 500 | |a Date Revised 04.03.2014 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2013 Wiley Periodicals, Inc. and the American Pharmacists Association. | ||
| 520 | |a There is a debate on the dose dependency, concentration-effect, hence, the beneficial effect of glucosamine (GlcN), a widely used anti-inflammatory natural product. We investigated dose/concentration-effect relationship and determined its minimum effective dose/concentration in rats with adjuvant arthritis (AA, Mycobacterium butyricum in squalene) both as preventive and ameliorating interventions. To control already emerged arthritis, rats received oral doses of placebo or 160 mg/kg.day(-1) GlcN for 6 days. For prevention, rats were orally administered 0, 20, 40, 80, or 160 mg/kg.day(-1) GlcN commencing on the day of adjuvant injection. The arthritis index (AI), serum nitrite, and body weight were recorded. Subsequently, animals were cannulated in the right jugular veins and blood samples were collected for the determination of GlcN. GlcN ameliorated and, dose-dependently, prevented AA. It also controlled nitrite. AI was inversely correlated with GlcN dose, maximum plasma concentration, and the area under the concentration curve. Minimum effective dose was approximately 40 mg/kg.day(-1) that correspond to maximum plasma concentration of 1.37 ± 0.24 mg/L, close to 1.6 mg/L reported for pharmaceutical grades of GlcN to humans. GlcN efficacy is dose and concentration dependent. If the data extrapolated to humans, a higher than the commonly tested 1500 mg/kg dosage regimen may provide more clear treatment outcomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a adjuvant arthritis | |
| 650 | 4 | |a dose-effect correlation | |
| 650 | 4 | |a drug effects | |
| 650 | 4 | |a minimum effective dose | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 4 | |a rat | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Interleukin-1beta |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Nitrites |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a Glucosamine |2 NLM | |
| 650 | 7 | |a N08U5BOQ1K |2 NLM | |
| 700 | 1 | |a Kohan, M H Gilzad |e verfasserin |4 aut | |
| 700 | 1 | |a Asghar, Waheed |e verfasserin |4 aut | |
| 700 | 1 | |a Jamali, Fakhreddin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of pharmaceutical sciences |d 1961 |g 103(2014), 2 vom: 01. Feb., Seite 760-7 |w (DE-627)NLM000006394 |x 1520-6017 |7 nnns |
| 773 | 1 | 8 | |g volume:103 |g year:2014 |g number:2 |g day:01 |g month:02 |g pages:760-7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jps.23819 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 103 |j 2014 |e 2 |b 01 |c 02 |h 760-7 | ||